MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
27.38
+0.83
+3.13%
Opening 11:40 12/05 EST
OPEN
26.75
PREV CLOSE
26.55
HIGH
27.46
LOW
26.74
VOLUME
969.60K
TURNOVER
--
52 WEEK HIGH
27.46
52 WEEK LOW
13.40
MARKET CAP
4.63B
P/E (TTM)
17.64
1D
5D
1M
3M
1Y
5Y
1D
Acadia Pharmaceuticals (ACAD): Reassessing Valuation After Strong Q3 Earnings Beat and Higher Analyst Price Targets
Simply Wall St · 15h ago
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Seeking Alpha · 17h ago
ACADIA Pharmaceuticals (ACAD) Receives a Buy from UBS
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), ACADIA Pharmaceuticals (ACAD) and Arcellx Inc (ACLX)
TipRanks · 1d ago
Should ACADIA’s Earnings Beat and Conference Highlights Require Action From ACADIA Pharmaceuticals (ACAD) Investors?
Simply Wall St · 1d ago
ACADIA Pharmaceuticals Is Maintained at Neutral by Mizuho
Dow Jones · 3d ago
ACADIA Pharmaceuticals Price Target Raised to $29.00/Share From $24.00 by Mizuho
Dow Jones · 3d ago
Mizuho Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $29
Benzinga · 3d ago
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.